PTX 5.00% 4.2¢ prescient therapeutics limited

PTX Media related, page-1350

  1. 1,502 Posts.
    lightbulb Created with Sketch. 381
    Health Kick Podcast: Prescient Therapeutics an emerging global leader in the next generation of personalised cancer therapies.
    Health & Biotech
    July 11, 2023 | Tim Boreham


    *’s resident health and biotech expert Tim Boreham is putting down the microscope and picking up the microphone for another instalment of The Health Kick Podcast.

    In this episode Tim chats to Steven Yatomi-Clarke, CEO of Prescient Therapeutics (ASXTX).
    Prescient Therapeutics is a clinical stage oncology company developing personalised medicine approaches to cancer, including targeted and cellular therapies.

    The company has continued to make solid progress on all fronts, with positive results from the company’s clinical programs underline its position as an emerging global leader in the next generation of personalised cancer therapies.

    Tune in below to hear Steven discuss the encouraging activity of its targeted therapy PTX-100 program.

    https://megaphone.link/ESCSC4802199730
 
watchlist Created with Sketch. Add PTX (ASX) to my watchlist
(20min delay)
Last
4.2¢
Change
0.002(5.00%)
Mkt cap ! $33.82M
Open High Low Value Volume
4.2¢ 4.2¢ 4.1¢ $1.134K 27.05K

Buyers (Bids)

No. Vol. Price($)
1 242158 4.1¢
 

Sellers (Offers)

Price($) Vol. No.
4.2¢ 102692 2
View Market Depth
Last trade - 16.10pm 12/07/2024 (20 minute delay) ?
PTX (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.